The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer
Abstract Background The relationship between KRAS mutations and the risk of venous thromboembolism (VTE) recurrence in metastatic colorectal cancer (mCRC) patients with established cancer-associated thrombosis (CAT) remains uncertain. This study aims to (1) evaluate the predictive value of seven KRA...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03843-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850201488714891264 |
|---|---|
| author | Zhikun Liang Xiaoyan Huang Jieling Mao Jingwen Xie Xiaoyan Li Li Qin |
| author_facet | Zhikun Liang Xiaoyan Huang Jieling Mao Jingwen Xie Xiaoyan Li Li Qin |
| author_sort | Zhikun Liang |
| collection | DOAJ |
| description | Abstract Background The relationship between KRAS mutations and the risk of venous thromboembolism (VTE) recurrence in metastatic colorectal cancer (mCRC) patients with established cancer-associated thrombosis (CAT) remains uncertain. This study aims to (1) evaluate the predictive value of seven KRAS mutation subtypes for VTE recurrence and (2) assess the impact of incorporating these mutations into two existing VTE risk scores: the Khorana score and the Ottawa score. Methods Between 2019 and 2023, we identified patients with histologically confirmed mCRC who had symptomatic or incidental index VTE and received anticoagulation therapy. Regression analyses were conducted to calculate hazard ratios (HRs) for recurrent VTE associated with the seven KRAS mutation subtypes. We used receiver operating characteristic (ROC) curves to assess the performance of both the original scores and the modified scores that included KRAS mutations. To quantify the improvements of the modified scores, we calculated the net reclassification improvement (NRI). Results A total of 2,195 patients were enrolled. KRAS G12C, KRAS G12A, and KRAS G13D mutations were significantly associated with a higher risk of recurrent VTE compared to other subtypes, with HRs of 1.84 (95% CI: 1.09–2.97), 2.02 (95% CI: 1.07–3.79), and 1.55 (95% CI: 1.02–2.27), respectively. The original Khorana and Ottawa scores demonstrated moderate predictive ability for VTE recurrence, each with an area under the ROC curve (ROC-AUC) of 0.56 (95% CI: 0.52–0.60). Incorporating the KRAS G12C, KRAS G12A, and KRAS G13D mutations improved the AUCs to 0.70 (95% CI: 0.67–0.74) for the modified Khorana score and 0.71 (95% CI: 0.67–0.74) for the modified Ottawa score. After dichotomizing risk using thresholds from ROC analysis, the NRI values were 0.54 (95% CI: 0.43–0.65) for the modified Khorana score and 0.48 (95% CI: 0.37–0.60) for the modified Ottawa score. Conclusions The KRAS G12C, KRAS G12A, and KRAS G13D mutations are significantly associated with an increased risk of recurrent VTE. Incorporating these specific KRAS mutations into existing risk scores may enhance their predictive accuracy for recurrent VTE in patients with mCRC. |
| format | Article |
| id | doaj-art-44d6aae857b2434da5e87eb0fa7aa85d |
| institution | OA Journals |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-44d6aae857b2434da5e87eb0fa7aa85d2025-08-20T02:12:01ZengBMCBMC Gastroenterology1471-230X2025-04-0125111210.1186/s12876-025-03843-wThe impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancerZhikun Liang0Xiaoyan Huang1Jieling Mao2Jingwen Xie3Xiaoyan Li4Li Qin5Department of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-sen UniversityDepartment of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-sen UniversityDepartment of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-sen UniversityDepartment of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-sen UniversityDepartment of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-sen UniversityDepartment of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-sen UniversityAbstract Background The relationship between KRAS mutations and the risk of venous thromboembolism (VTE) recurrence in metastatic colorectal cancer (mCRC) patients with established cancer-associated thrombosis (CAT) remains uncertain. This study aims to (1) evaluate the predictive value of seven KRAS mutation subtypes for VTE recurrence and (2) assess the impact of incorporating these mutations into two existing VTE risk scores: the Khorana score and the Ottawa score. Methods Between 2019 and 2023, we identified patients with histologically confirmed mCRC who had symptomatic or incidental index VTE and received anticoagulation therapy. Regression analyses were conducted to calculate hazard ratios (HRs) for recurrent VTE associated with the seven KRAS mutation subtypes. We used receiver operating characteristic (ROC) curves to assess the performance of both the original scores and the modified scores that included KRAS mutations. To quantify the improvements of the modified scores, we calculated the net reclassification improvement (NRI). Results A total of 2,195 patients were enrolled. KRAS G12C, KRAS G12A, and KRAS G13D mutations were significantly associated with a higher risk of recurrent VTE compared to other subtypes, with HRs of 1.84 (95% CI: 1.09–2.97), 2.02 (95% CI: 1.07–3.79), and 1.55 (95% CI: 1.02–2.27), respectively. The original Khorana and Ottawa scores demonstrated moderate predictive ability for VTE recurrence, each with an area under the ROC curve (ROC-AUC) of 0.56 (95% CI: 0.52–0.60). Incorporating the KRAS G12C, KRAS G12A, and KRAS G13D mutations improved the AUCs to 0.70 (95% CI: 0.67–0.74) for the modified Khorana score and 0.71 (95% CI: 0.67–0.74) for the modified Ottawa score. After dichotomizing risk using thresholds from ROC analysis, the NRI values were 0.54 (95% CI: 0.43–0.65) for the modified Khorana score and 0.48 (95% CI: 0.37–0.60) for the modified Ottawa score. Conclusions The KRAS G12C, KRAS G12A, and KRAS G13D mutations are significantly associated with an increased risk of recurrent VTE. Incorporating these specific KRAS mutations into existing risk scores may enhance their predictive accuracy for recurrent VTE in patients with mCRC.https://doi.org/10.1186/s12876-025-03843-wMetastatic colorectal cancerVenous thromboembolismRisk assessment modelKRAS mutation |
| spellingShingle | Zhikun Liang Xiaoyan Huang Jieling Mao Jingwen Xie Xiaoyan Li Li Qin The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer BMC Gastroenterology Metastatic colorectal cancer Venous thromboembolism Risk assessment model KRAS mutation |
| title | The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer |
| title_full | The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer |
| title_fullStr | The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer |
| title_full_unstemmed | The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer |
| title_short | The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer |
| title_sort | impact of kras mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer |
| topic | Metastatic colorectal cancer Venous thromboembolism Risk assessment model KRAS mutation |
| url | https://doi.org/10.1186/s12876-025-03843-w |
| work_keys_str_mv | AT zhikunliang theimpactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT xiaoyanhuang theimpactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT jielingmao theimpactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT jingwenxie theimpactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT xiaoyanli theimpactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT liqin theimpactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT zhikunliang impactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT xiaoyanhuang impactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT jielingmao impactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT jingwenxie impactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT xiaoyanli impactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer AT liqin impactofkrasmutationsonriskofvenousthromboembolismrecurrenceinpatientswithmetastaticcolorectalcancer |